Abstract
Diabetic Macular Edema (DME) and neovascular Age-related Macular Degeneration (nAMD) cause vision loss leading to morbidity and loss of health-related quality of life. Treatment in the country is based on anti-vascular endothelial growth factor (VEGF). Our objective is to estimate the economic burden generated by these diseases in Guatemala to have information that allows decision-makers to estimate the magnitude of this problem in the country.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
